Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An oral antisense oligonucleotide for PCSK9 inhibition.
Gennemark P, Walter K, Clemmensen N, Rekić D, Nilsson CAM, Knöchel J, Hölttä M, Wernevik L, Rosengren B, Kakol-Palm D, Wang Y, Yu RZ, Geary RS, Riney SJ, Monia BP, Isaksson R, Jansson-Löfmark R, Rocha CSJ, Lindén D, Hurt-Camejo E, Crooke R, Tillman L, Rydén-Bergsten T, Carlsson B, Andersson U, Elebring M, Tivesten A, Davies N. Gennemark P, et al. Among authors: wernevik l. Sci Transl Med. 2021 May 12;13(593):eabe9117. doi: 10.1126/scitranslmed.abe9117. Sci Transl Med. 2021. PMID: 33980578
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.
Rekić D, Azarov I, Knöchel J, Sokolov V, Nilsson C, Wernevik L, Han D, Rydén-Bergsten T, Ebrahimi A, Dota C, Carlsson B. Rekić D, et al. Among authors: wernevik l. Br J Clin Pharmacol. 2022 Nov;88(11):4839-4844. doi: 10.1111/bcp.15425. Epub 2022 Jun 10. Br J Clin Pharmacol. 2022. PMID: 35653229 Free article.
A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.
Knöchel J, Nilsson C, Carlsson B, Wernevik L, Hofherr A, Gennemark P, Jansson-Löfmark R, Isaksson R, Rydén-Bergsten T, Hamrén B, Rekić D. Knöchel J, et al. Among authors: wernevik l. CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1569-1577. doi: 10.1002/psp4.12866. Epub 2022 Oct 1. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36126230 Free PMC article. Clinical Trial.
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.
Squire IB, Gabrielsen A, Greasley PJ, Wernevik L, Hartleib-Geschwindner J, Holden J, Johansson S, Rudvik A, Sánchez J, Bamberg K, Melin J, Whittaker A. Squire IB, et al. Among authors: wernevik l. Clin Transl Sci. 2022 Oct;15(10):2493-2504. doi: 10.1111/cts.13377. Epub 2022 Aug 20. Clin Transl Sci. 2022. PMID: 35971596 Free PMC article. Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
Whittaker A, Kragh ÅM, Hartleib-Geschwindner J, Albayaty M, Backlund A, Greasley PJ, Heijer M, Kjaer M, Forte P, Unwin R, Wernevik L, Ericsson H. Whittaker A, et al. Among authors: wernevik l. Clin Transl Sci. 2020 Mar;13(2):275-283. doi: 10.1111/cts.12705. Epub 2019 Oct 30. Clin Transl Sci. 2020. PMID: 31584739 Free PMC article. Clinical Trial.
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
Erlandsson F, Albayaty M, Chialda L, Ericsson H, Amilon C, Nelander K, Jansson-Löfmark R, Wernevik L, Kjaer M, Bamberg K, Hartleib-Geschwindner J. Erlandsson F, et al. Among authors: wernevik l. Br J Clin Pharmacol. 2018 Jul;84(7):1486-1493. doi: 10.1111/bcp.13562. Epub 2018 Apr 22. Br J Clin Pharmacol. 2018. PMID: 29468715 Free PMC article. Clinical Trial.
Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide.
Clewe O, Rekić D, Quartino AL, Carlsson B, Higashimori M, Wernevik L, Hofherr A, Rydén-Bergsten T, Nilsson C, Knöchel J. Clewe O, et al. Among authors: wernevik l. Br J Clin Pharmacol. 2024 Mar 19. doi: 10.1111/bcp.16046. Online ahead of print. Br J Clin Pharmacol. 2024. PMID: 38504437